Sonoma Pharmaceuticals, Inc. (SNOA): Price and Financial Metrics
GET POWR RATINGS... FREE!
SNOA POWR Grades
- Value is the dimension where SNOA ranks best; there it ranks ahead of 85.43% of US stocks.
- The strongest trend for SNOA is in Growth, which has been heading down over the past 69 days.
- SNOA's current lowest rank is in the Momentum metric (where it is better than 20.68% of US stocks).
SNOA Stock Summary
- SNOA has a market capitalization of $16,369,849 -- more than approximately only 2.41% of US stocks.
- Of note is the ratio of Sonoma Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; 98.05% of US stocks have a lower such ratio.
- In terms of volatility of its share price, SNOA is more volatile than just 14.36% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Sonoma Pharmaceuticals Inc are NBRV, OBLN, NBY, SHSP, and TC.
- SNOA's SEC filings can be seen here. And to visit Sonoma Pharmaceuticals Inc's official web site, go to www.sonomapharma.com.
SNOA Stock Price Chart Interactive Chart >
SNOA Price/Volume Stats
| Current price | $7.65 | 52-week high | $15.19 |
| Prev. close | $7.82 | 52-week low | $6.00 |
| Day low | $7.59 | Volume | 6,500 |
| Day high | $7.85 | Avg. volume | 187,008 |
| 50-day MA | $7.80 | Dividend yield | N/A |
| 200-day MA | $7.84 | Market Cap | 15.89M |
Sonoma Pharmaceuticals, Inc. (SNOA) Company Bio
Sonoma Pharmaceuticals, Inc. operates as a pharmaceutical company. The Company develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. Sonoma Pharmaceuticals serves customers worldwide.
Latest SNOA News From Around the Web
Below are the latest news stories about Sonoma Pharmaceuticals Inc that investors may wish to consider to help them evaluate SNOA as an investment opportunity.
31 Stocks Moving in Thursday's Pre-Market SessionGainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA ) rose 44.4% to $10.73 in pre-market trading after the company, and EMC Pharma, announced an exclusive partnership to expand commercial channels of the Microcyn-based Rx dermatology and eye care products nationwide. AeroCentury Corp. (NYSE: ACY ) rose 38.3% to $ 4.91 in pre-market trading. The company recently reported that it filed a petition for a Chapter 11 reorganization. P&F Industries, Inc. (NASDAQ: PFIN ) shares rose 27.5% to $8.39 in pre-market trading after gaining over 9% on Wednesday. The company recently reported results for the year ended December 31, 2020. Psychemedics Corporation (NASDAQ: PMD ) rose 25.8% to $7.80 in pre-market trading. The company recently reported a Q4 loss. Jaguar Health, Inc. (NASDAQ: JAGX ) rose 17.8... |
Sonoma Pharma Stock Is Trading Higher After Distribution Pact With EMC PharmaSonoma Pharmaceuticals Inc (NASDAQ: SNOA ) has entered into an agreement with EMC Pharma LLC for the exclusive right to manage, market, and distribute Sonoma's HOCl-based prescription dermatology and eye care … Full story available on Benzinga.com |
Sonoma Pharmaceuticals and EMC Pharma Announce an Exclusive Partnership to Expand Commercial Channels of the Microcyn®-based Rx Dermatology and Eye Care Products NationwideSonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, and dermatological conditions, today announced that it has entered into an agreement with EMC Pharma, LLC for the exclusive right to manage, market and distribute Sonoma’s HOCl-based prescription dermatology and eye care products in the United States for an initial term of five years, subject to extension. EMC Pharma will also have a non-exclusive agreement to manage, market and distribute certain Microcyn-based wound care products into government channels. |
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Sonoma Pharmaceuticals, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – SNOAWHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public. |
Sonoma Pharmaceuticals to Present at Upcoming Spring Virtual Investor ConferencesWOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, today announced that CEO Amy Trombly and CFO Jerry Dvonch will present at the following upcoming virtual conferences. Event H.C. Wainwright Global Life Sciences Conference Date March 9-10, 2021 |
SNOA Price Returns
| 1-mo | 1.86% |
| 3-mo | 3.66% |
| 6-mo | -9.47% |
| 1-year | 17.87% |
| 3-year | -68.40% |
| 5-year | -81.32% |
| YTD | 5.37% |
| 2020 | 66.51% |
| 2019 | -31.77% |
| 2018 | -86.97% |
| 2017 | 8.13% |
| 2016 | -12.35% |
Continue Researching SNOA
Want to see what other sources are saying about Sonoma Pharmaceuticals Inc's financials and stock price? Try the links below:Sonoma Pharmaceuticals Inc (SNOA) Stock Price | Nasdaq
Sonoma Pharmaceuticals Inc (SNOA) Stock Quote, History and News - Yahoo Finance
Sonoma Pharmaceuticals Inc (SNOA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...